Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs ProShares Ultra Gold ETF (UGL) Price & Performance

Eli Lilly And CoTrade
ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs ProShares Ultra Gold ETF — how do they compare? Eli Lilly And Co trades at $1,225.53 (market cap $1.08T), while ProShares Ultra Gold ETF trades at $52.58. The key difference: Eli Lilly And Co pays a 0.57% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals.

LLYUGL
Market Cap
$1.08T
Sector
HealthLeveraged / Inverse
52-Week High
$1.24K$85.62
52-Week Low
$639.43$34.37
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

ProShares Ultra Gold ETF

UGL is trading at $52.81, up 2.13% with a bullish technical signal from moving averages, though oscillators show bearish divergence. The stock faces resistance at $53 with support at $51. Recent gold market strength from inflation data and geopolitical tensions provides positive momentum, though financial ratios remain unavailable for fundamental assessment.

The outlook for UGL appears cautiously optimistic given gold's recent performance, but investment decisions require verified financial data currently missing. Key risks include gold price volatility and reliance on broader commodity trends. Analyst consensus and institutional positioning data are needed for comprehensive evaluation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.

Read more on UGL